sb 203580 has been researched along with nagilactone c in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (nagilactone c) | Trials (nagilactone c) | Recent Studies (post-2010) (nagilactone c) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 18 | 0 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clutter, MR; Crane, JM; Krutzik, PO; Nolan, GP | 1 |
1 other study(ies) available for sb 203580 and nagilactone c
| Article | Year |
|---|---|
High-content single-cell drug screening with phosphospecific flow cytometry.
Topics: Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Janus Kinases; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Phosphorus; Sensitivity and Specificity; Signal Transduction; STAT Transcription Factors | 2008 |